Gastrointestinal Cancers Symposium

The latest news from ASCO GI, including researcher interviews and physician perspective.


Meeting News Coverage

SPACE: Addition of sorafenib delayed progression in intermediate HCC

February 7, 2012
2012 Gastrointestinal Cancers Symposium SAN FRANCISCO — Sorafenib improved time to progression without increasing toxicity when added to…
Meeting News CoveragePerspective

Cetuximab, brivanib failed to extend OS in metastatic colorectal carcinoma

February 6, 2012
2012 Gastrointestinal Cancers Symposium SAN FRANCISCO — Despite improvements in PFS and objective response, the combination of cetuximab and…
Meeting News Coverage

Monoclonal antibody detected early-stage pancreatic cancer marker

January 31, 2012
2012 Gastrointestinal Cancers Symposium SAN FRANCISCO — A test using a monoclonal antibody to detect PAM4 protein and CA19-9 markers was able to…
Meeting News Coverage

Study identified predictive factors for neuroendocrine tumor progression

January 30, 2012
2012 Gastrointestinal Cancers Symposium SAN FRANCISCO — Researchers identified that certain factors were associated with a greater probability of …
Meeting News Coverage

Biomarkers detected patients at risk for esophageal cancer

January 27, 2012
2012 Gastrointestinal Cancers Symposium SAN FRANCISCO — Researchers identified biomarkers that could improve early detection of esophageal cancer …
Meeting News Coverage

Regorafenib improved survival, delayed progression in colorectal cancer

January 26, 2012
2012 Gastrointestinal Cancers Symposium SAN FRANCISCO — The investigational drug regorafenib extended survival in patients with …
Meeting News Coverage

NO16968: Xelox improved 7-year OS in advanced colon cancer

January 23, 2012
2012 Gastrointestinal Cancers Symposium SAN FRANCISCO — Patients with stage III colon cancer assigned to Xelox realized a significant improvement…
Meeting News CoveragePerspective

GRANITE-1: Second-line everolimus did not extend OS for advanced gastric cancer

January 20, 2012
2012 Gastrointestinal Cancers Symposium SAN FRANCISCO — Patients assigned to everolimus monotherapy did not enjoy a survival benefit, according to…
Meeting News CoverageMeeting HighlightsPerspective

Inappropriate use of medical imaging may be more widespread than previously thought

HemOnc Today, March 25, 2011
ASCO 2011 Genitourinary Cancers Symposium ORLANDO — More than one-third of men at low risk for prostate cancer underwent unnecessary medical…
Meeting News CoverageMeeting Highlights

Higher baseline PSA may be linked to increased prostate cancer risk

HemOnc Today, March 10, 2011
ASCO 2011 Genitourinary Cancers Symposium ORLANDO — The risk for prostate cancer and aggressive prostate cancer increased as PSA scores increased…